Recently, Quintás-Cardama et al. 87 demonstrated that the p53 pathway is frequently disrupted in AML, not just via TP53 mutations/deletions but also via a molecular background permissive to the transformation capability of p53. This evidence concerns the gene TP53 and acute myeloid leukemia.